ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2025
Deciphering the pharmacological mechanisms of salidroside in cervical cancer by combining network pharmacology, molecular docking, and in vitro studies.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cervical cancer is one of the major and serious risks to women. Salidroside, a natural compound, shows promise in treating cervical cancer. However, its specific molecular mechanisms remain unclear and require further investigation. This study aimed to elucidate the pharmacological activity of salidroside and its underlying molecular mechanisms in cervical cancer, employing network pharmacology, molecular docking, and experimental approaches. Genes associated with cervical cancer were gathered from The Cancer Genome Atlas Program (TCGA), Gene Expression Omnibus (GEO) databases, and network pharmacology. Furthermore, we integrated the drug targets with the disease targets pertinent to cervical cancer, subsequently conducting analyses utilizing the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) to explain the pharmacological pathways through which salidroside operates in the milieu of cervical cancer. Survival analysis was performed to screen the core therapeutic targets of salidroside. Salidroside constituents and hub genes binding affinity were assessed by molecular docking studies. In vitro experiments, including Cell Counting Kit-8 (CCK-8) assays, flow cytometry, and western blotting, were performed to further validate the computational findings. Study findings revealed that salidroside inhibited the cervical cancer cell progression, reduced viability, and induced apoptosis.Ten target genes related to salidroside's anti-cancer effects have been identified. Survival analysis revealed that MMP1 and MMP3 exhibited the highest binding capability among all the target genes. Molecular docking indicated that the salidroside's active entities showed a strong binding tendency with the MMP1 and MMP3 genes. Western blot analysis revealed that it significantly reduced the expression of MMP-1 and MMP-3. In Vitro studies suggested that suppressing MMP1 and MMP3 genes might be responsible for salidroside's anticancer effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.